However, since Midostaurin was the first drug approved in an AML genetic subgroup characterized by a specific gene mutation, this represents a starting point for novel therapy employing additional targeted agents, including second- and third-generation FLT3 inhibitors in ongoing clinical trials. Here, FLT3 is linked to acute myeloid leukemia.